Hans Ericsson

BioPharmaceuticals R&D
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics and the Pharmacokinetics of Balcinrenone When Dosed with a P-gp Inhibitor.

Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics and the Pharmacokinetics of Balcinrenone When Dosed with a P-gp Inhibitor.

Journal: Journal of clinical pharmacology

Published: March 26, 2026

Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat.

Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat.

Journal: Pharmacology research & perspectives

Published: December 16, 2025

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

Journal: British journal of clinical pharmacology

Published: November 06, 2025

Population Pharmacokinetic Analysis of Balcinrenone in Healthy Participants and Participants with Heart Failure and Chronic Kidney Disease.

Population Pharmacokinetic Analysis of Balcinrenone in Healthy Participants and Participants with Heart Failure and Chronic Kidney Disease.

Journal: Clinical pharmacokinetics

Published: March 21, 2025

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

Journal: British journal of clinical pharmacology

Published: December 06, 2024

Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers.

Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers.

Journal: Clinical drug investigation

Published: October 14, 2024

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat.

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat.

Journal: British journal of clinical pharmacology

Published: May 17, 2024

Disposition of orally administered atuliflapon, a novel 5-lipoxygenase-activating protein inhibitor in healthy participants.

Disposition of orally administered atuliflapon, a novel 5-lipoxygenase-activating protein inhibitor in healthy participants.

Journal: Pharmacology research & perspectives

Published: March 21, 2024

A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam.

A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam.

Journal: British journal of clinical pharmacology

Published: January 19, 2024

The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses.

The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses.

Journal: Pharmacology research & perspectives

Published: November 22, 2023

Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.

Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.

Journal: European journal of heart failure

Published: March 01, 2023

Mass Balance and Absorption, Distribution, Metabolism, and Excretion Properties of Balcinrenone following Oral Administration in Combination with Intravenous Microtracer in Healthy Subjects.

Mass Balance and Absorption, Distribution, Metabolism, and Excretion Properties of Balcinrenone following Oral Administration in Combination with Intravenous Microtracer in Healthy Subjects.

Journal: Drug metabolism and disposition: the biological fate of chemicals

Published: December 21, 2022

Showing 1-12 of 30

Last Updated: 09/26/2026